Epilepsy Treatment Complacency in Patients, Caregivers, and Health Care Professionals
- PMID: 34824892
- PMCID: PMC8610521
- DOI: 10.1212/CPJ.0000000000001066
Epilepsy Treatment Complacency in Patients, Caregivers, and Health Care Professionals
Abstract
Objective: To explore the perspectives of adult patients with epilepsy, caregivers, and health care professionals (HCPs) on treatment for seizures and treatment decisions, we developed and administered the STEP Survey (Seize the Truth of Epilepsy Perceptions).
Methods: Participants were recruited from online panel M3 and by Rare Patient Voice and completed the self-administered online STEP Survey. Analysis of variance and chi-square tests were used for group comparisons.
Results: The STEP Survey was completed by 400 adult patients, 201 caregivers, and 258 HCPs. Patients estimated reporting 45% of their seizures to their HCP, whereas caregivers estimated 83% and HCPs estimated 73% were reported. The most common reason for not reporting seizures was that the seizures were not serious enough to mention (patients 57%; caregivers 66%). A minority of patients (25%) and caregivers (30%) were very or extremely likely to ask their HCP about changing antiseizure medication (ASM) in the next 12 months. The HCP was most frequently selected by patients, caregivers, and HCPs as the person who initiates discussion of changing ASMs (patients 73%/caregivers 66%/HCPs 75%) and increasing ASM dosage (patients 77%/caregivers 68%/HCPs 81%). A majority of patients (65%) and caregivers (68%) somewhat or strongly agreed that they do not change ASMs due to fear of getting worse. HCPs perceive this fear less often, stating that 50% of their patients feel afraid when a second ASM was added.
Conclusions: Improved reporting of all seizures, discussion of treatment changes, and the impact of fear on treatment decisions provide opportunities to reduce complacency and optimize patient outcomes.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Figures





Similar articles
-
Patient, caregiver, and healthcare professional perspectives on seizure control and treatment goals.Epilepsy Behav. 2021 Apr;117:107816. doi: 10.1016/j.yebeh.2021.107816. Epub 2021 Feb 21. Epilepsy Behav. 2021. PMID: 33626491
-
Influence of titration of antiseizure medications on treatment selection: Results of an online survey with clinicians in the United States.Epilepsy Behav. 2021 Apr;117:107840. doi: 10.1016/j.yebeh.2021.107840. Epub 2021 Feb 21. Epilepsy Behav. 2021. PMID: 33626489
-
To reveal or conceal? Adult patient perspectives on SUDEP disclosure.Epilepsy Behav. 2018 Sep;86:79-84. doi: 10.1016/j.yebeh.2018.06.026. Epub 2018 Jul 9. Epilepsy Behav. 2018. PMID: 30001909
-
Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.Health Technol Assess. 2011 May;15(20):1-234, iii-iv. doi: 10.3310/hta15200. Health Technol Assess. 2011. PMID: 21545758 Review.
-
Health care practitioners' perceptions of psychogenic nonepileptic seizures: A systematic review of qualitative and quantitative studies.Epilepsia. 2018 Jun;59(6):1109-1123. doi: 10.1111/epi.14189. Epub 2018 May 11. Epilepsia. 2018. PMID: 29750340
References
-
- Glauser T, Ben-Menachem E, Bourgeois B, et al. . ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47:1094–1120. - PubMed
-
- Glauser T, Ben-Menachem E, Bourgeois B, et al. . Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54:551–563. - PubMed